Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Dow
Baxter
Harvard Business School
Mallinckrodt

Last Updated: May 26, 2022

Eravacycline dihydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for eravacycline dihydrochloride and what is the scope of patent protection?

Eravacycline dihydrochloride is the generic ingredient in one branded drug marketed by Tetraphase Pharms and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eravacycline dihydrochloride has seventy-eight patent family members in thirty-two countries.

Summary for eravacycline dihydrochloride
International Patents:78
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 18
Clinical Trials: 10
Patent Applications: 3
DailyMed Link:eravacycline dihydrochloride at DailyMed
Recent Clinical Trials for eravacycline dihydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Tetraphase Pharmaceuticals, Inc.Phase 3
Tetraphase Pharmaceuticals, Inc.Phase 1
Department of Health and Human ServicesPhase 1

See all eravacycline dihydrochloride clinical trials

US Patents and Regulatory Information for eravacycline dihydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-002 Jun 3, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-002 Jun 3, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for eravacycline dihydrochloride

Country Patent Number Title Estimated Expiration
Denmark 2682387 See Plans and Pricing
China 102177134 C7-fluoro substituted tetracycline compounds See Plans and Pricing
Denmark 2323972 See Plans and Pricing
South Korea 20190065414 에라바사이클린의 결정질 형태 See Plans and Pricing
Norway 2019010 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for eravacycline dihydrochloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2323972 LUC00107 Luxembourg See Plans and Pricing PRODUCT NAME: ERAVACYCLINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924
2323972 1990014-1 Sweden See Plans and Pricing PRODUCT NAME: ERAVACYCLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/18/1312 20180924
2323972 2019C/511 Belgium See Plans and Pricing PRODUCT NAME: ERAVACYCLINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924
2323972 19C1012 France See Plans and Pricing PRODUCT NAME: ERAVACYCLINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE:EU/1/18/1312 20180924
2323972 PA2019009,C2323972 Lithuania See Plans and Pricing PRODUCT NAME: ERAVACIKLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1312 C(2018)6231 20180920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Harvard Business School
McKinsey
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.